العربية
简体中文
Français
Português
Русский
Español
James Lind Library
Illustrating the development of fair tests of treatments in health care
Home
About the Library
Topics
Essays
Records
Articles
Blogs
Menu
Home
About the Library
Topics
Essays
Records
Articles
Blogs
Search
ADDITIONAL METHODS - SPONSOR BIAS
SORT
author
▲
date
clear filters
14 RECORDS
FILTER RECORDS BY
PERIOD
<18th Century
18th Century
19th Century
1900-1949
1950-1999
21st Century
ORIGIN OF AUTHOR
American
Arab (medieval)
Australian
Austrian
Belgian
British
Canadian
Chinese
Chinese (medieval)
Colombian
Croatian
Czech
Danish
Dutch
Egyptian
Egyptian (ancient)
English (medieval)
Finnish
Flemish
French
German
Greek
Greek (ancient)
Hebrew (ancient)
Hungarian
Indian
Indonesian
Irish
Israeli
Italian
Italian (medieval)
Japanese
Multinational
Norwegian
Persian (medieval)
Polish
Portuguese
Roman (ancient)
Russian
South African
Spanish
Swedish
Swiss
Unknown
Vietnamese
Sollmann T (1917)
The crucial test of therapeutic evidence. JAMA 69:198-199.
View
Hemminki E (1980)
Study of information submitted by drug companies to licensing authorities. BMJ 280:833-6.
View
Davidson RA (1986)
Source of funding and outcome of clinical trials. Journal of General Internal Medicine 1:156-158.
View
Gøtzsche PC (1987)
Reference bias in reports of drug trials. BMJ 295:654-656.
View
Blumenthal D, Gluck M, Louis KS, Stoto MA, Wise D. (1996)
Academic-industry relationships in the life sciences - an industry survey. New England Journal of Medicine 334:368-73.
View
Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman GH (2000)
The uncertainty principle and industry-sponsored research. Lancet 356:635-638.
View
Lexchin J, Bero LA, Djulbegovic B, Clark O (2003)
Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326:1167-70.
View
Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B (2003)
Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326:1171-3.
View
Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E (2004)
Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet; 363:1341-1345.
View
Yank V, Rennie D, Bero LA (2007)
Financial ties and concordance between results: retrospective cohort study. BMJ 335:1202-5. doi:10.1136/bmj.39376.447211.
View
Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, Clarke M, Bennett CL (2008)
Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the national cancer institute-sponsored cooperative oncology groups, 1955 to 2006. Archives of Internal Medicine. 168:632-42.
View
Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008)
Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 358:252-60.
View
Rising K, Bacchetti P, Bero L (2008)
Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 5(11): e217. doi:10.1371/journal.pmed.0050217
View
Psaty BM, Kronmal RA (2008)
Reporting mortality findings in trials of Rofecoxib for Alzheimer disease or cognitive impairment. JAMA 299:1813-1817.
View
methods
Principles of testing
Pre-clinical
Dramatic effects
N-of-1 crossover
Crossover tests
Cluster allocation
Factorial design
Double dummy
Placebo effects